Head-to-head · WeighScore
Boston Medical Group vs yourEra
The verdict
yourEra takes it — 83.8/100 to 61.9/100.
yourEra grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A both-molecule compounded program that publishes its prices up front — semaglutide $199/mo, tirzepatide $299/mo — across a 50-state clinician network, with an optional coaching-plus-labs membership and a NAD+/microdosing menu on the side.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | yourEra |
|---|---|---|
| WeighScore | 61.9/100 | 83.8/100 |
| Grade | C | B |
| Scorecard rank | #279 | #13 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $199/mo |
| Tirzepatide | Not disclosed | $299/mo |
| Coverage | 7 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #13 · B
Strengths
- Transparent, publicly listed pricing — many compounded competitors hide price behind a quiz
- Both semaglutide and tirzepatide, not a single-drug menu, plus NAD+ and microdosing lines
- Markets a 50-state licensed-clinician network; no insurance required, HSA/FSA accepted
- Optional yourEra Optimum membership adds 1:1 coaching, a nutritionist, at-home lab draws and wearables
Where it loses points
- Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
- Mid-market pricing ($199 sema / $299 tirz) — above the cheapest compounders
- No brand-name lane and no oral route — weekly injectable only
- Thin independent footprint; the 50-state and efficacy claims are self-reported
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.